The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility

  • Barber O
  • Miramontes I
  • Jain M
  • et al.
11Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rising antimicrobial resistance severely limits efforts to treat infections and is a cause for critical concern. Renewed interest in bacteriophage therapy has advanced understanding of the breadth of species capable of targeting bacterial antimicrobial resistance mechanisms, but many questions concerning ideal application remain unanswered. Rising antimicrobial resistance severely limits efforts to treat infections and is a cause for critical concern. Renewed interest in bacteriophage therapy has advanced understanding of the breadth of species capable of targeting bacterial antimicrobial resistance mechanisms, but many questions concerning ideal application remain unanswered. The following minireview examines bacterial resistance mechanisms, the current state of bacteriophage therapy, and how bacteriophage therapy can augment strategies to combat resistance with a focus on the clinically relevant bacterium Pseudomonas aeruginosa , as well as the role of efflux pumps in antimicrobial resistance. Methods to prevent antimicrobial efflux using efflux pump inhibitors and phage steering, a type of bacteriophage therapy, are also covered. The evolutionary context underlying antimicrobial resistance and the need to include theory in the ongoing development of bacteriophage therapy are also discussed.

Cite

CITATION STYLE

APA

Barber, O. W., Miramontes, I. M., Jain, M., Ozer, E. A., & Hartmann, E. M. (2021). The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility. MSystems, 6(4). https://doi.org/10.1128/msystems.00218-21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free